Replicel Life Sciences Inc V.RP

Alternate Symbol(s): REPCF

Healthcare Biotechnology

RepliCel Life Sciences Inc. is a Canada-based regenerative medicine company. The Company is focused on developing cell therapies for aesthetic and orthopedic conditions, including aging/sun-damaged skin, pattern baldness, and chronic tendon degeneration. The Company’s cell therapy product pipeline is comprised of RCT-01 for tendon repair, RCS-01 for skin rejuvenation, and RCH-01 for hair restoration. RCH-01 is an autologous cell therapy utilizing dermal sheath cup (DSC) cells isolated from the hair follicle to treat androgenetic alopecia. RCS-01 is an autologous cell therapy utilizing non-bulbar dermal sheath (NBDS) cells, a type of fibroblast cell isolated from the hair follicle to repair and regenerate tissue. RCT-01 provides a source of collagen expressing cells to the site of injury, addressing the underlying cause of tendinosis. It has also developed an injection device, DermaPrecise, which improves the administration of its cell therapy products and certain other injectables.

TSXV:RP - Post by User

Replicel Life Sciences Inc

Bullboard Posts

Comment by RPINVESTOR1on Oct 20, 2020 1:55pm

76 Views

Post# 31748951

RE:RE:Twitter

Ingiboy:-

You can call me crazy but to me it could be a sale to Shiseido. This will probably be the last opportunity for Shiseido to buy the Company in a structure that is relatively simple - controlling world-wide rights minus China (incl. HK, Macao and Taiwan) for all of Replicel's products.

I cannot see Shiseido being satisfied with only the RCH-01 rights for Asia. If Shiseido does not move soon, the dermal injector rights will be sold to other companies and the Company will be more of a royalty operation and not as attractive to own. The chances of them then getting the remaining rights for RCH-01 will also probably lessen.

Bullboard Posts

Invest wiser with BMO's InvestorLine Platform features